NANOBIOTIX raises $100 million through a global offering

Biotechnology company Nanobiotix has completed a $100 million funding round through the full exercise of its over-allotment option. Following this transaction, the company issued a total of 2,218,467 common shares, including 259,178 American Depositary Shares (ADS) and 345,099 pre-funded warrants. The funds will be used to develop various projects, allocating 50% to 60% to platforms such as Nanoprimer.

The revenue is also expected to support the development of JNJ-1900 (NBTXR3) and cover the company's general expenses. Nanobiotix, listed on Euronext Paris and Nasdaq, anticipates that this funding round will be sufficient to finance its needs until 2029.